Department of Psychology, University of Zurich, Binzmühlestrasse 14/16, Zurich, Switzerland.
Department of Health Sciences, Helsana, Zurich, Switzerland.
BMC Psychiatry. 2019 Jun 24;19(1):196. doi: 10.1186/s12888-019-2178-4.
The aim of the study was to examine the prevalence of and factors associated with antidepressant (AD) prescriptions in order to draw a comprehensive picture of prescribing practices in Switzerland.
We conducted a population-based, cross-sectional descriptive study using a large Swiss healthcare claims database, covering approximately 13% of the Swiss population. AD prescription was determined by identifying patients (N = 105,663) with health claims data of at least 1 AD prescription in the year 2016. AD medication was identified using ATC-codes classified by the World Health Organisation. Univariate, bivariate and multivariate analyses using logistic regression were performed.
The extrapolated 1-year prevalence of AD prescription was 8.7% (95% CI, 8.7-8.8) with two thirds of AD recipients being female and the average age being 59 years (SD = 19.1). The regional distribution of prescription rates varied between cantons and ranged from 6.5 to 11.7%. Logistic regression revealed higher prescription rates among females compared to males (OR: 1.52) and an increased probability of AD prescription by age up until 54 years (OR: 2.25) and ≥ 85 years (OR: 2.32). Comorbidity is associated with higher odds (OR: 3.26 with 1-2 comorbidities) and enrollment in a managed care plan (compared to standard care) with lower odds for an AD prescription (OR: 0.85).
This study is the first in Switzerland to describe the prevalence of and factors associated with AD prescription based on a large health claims database reflecting routine care. The results provide important information about regional variation, prescription source, and potential over-prescription in the treatment of depressive disorders.
本研究旨在调查抗抑郁药(AD)处方的流行情况及相关因素,以全面了解瑞士的处方实践。
我们使用瑞士大型医疗保健索赔数据库进行了一项基于人群的横断面描述性研究,该数据库涵盖了约 13%的瑞士人口。通过确定 2016 年至少有 1 次 AD 处方的患者(N=105663)来确定 AD 处方。使用世界卫生组织分类的 ATC 代码识别 AD 药物。使用逻辑回归进行了单变量、双变量和多变量分析。
AD 处方的 1 年估计患病率为 8.7%(95%CI,8.7-8.8),三分之二的 AD 接受者为女性,平均年龄为 59 岁(SD=19.1)。处方率的区域分布在各州之间存在差异,范围为 6.5%至 11.7%。逻辑回归显示,女性的处方率高于男性(OR:1.52),年龄在 54 岁及以下(OR:2.25)和 85 岁及以上(OR:2.32)的 AD 处方概率增加。合并症与更高的 AD 处方可能性相关(OR:3.26,有 1-2 种合并症),与标准护理相比,管理式医疗计划的纳入与 AD 处方的可能性降低(OR:0.85)相关。
本研究是瑞士首次基于反映常规护理的大型医疗保健索赔数据库描述 AD 处方的流行情况和相关因素的研究。研究结果提供了有关地区差异、处方来源和抑郁障碍治疗中潜在过度处方的重要信息。